Literature DB >> 32633407

Glycyrrhizin improves inflammation and apoptosis via suppressing HMGB1 and PI3K/mTOR pathway in lipopolysaccharide-induced acute liver injury.

C-H Shen1, Z-Y Ma, J-H Li, R-D Li, Y-F Tao, Q-B Zhang, Z-X Wang.   

Abstract

OBJECTIVE: Acute liver injury (ALI) is mainly characterized by the symptom of metabolic disorders, homeostasis unbalance, and loss of liver function. There are no effective treatment methods at present stage except the liver transplantation. Effective treatment for early ALI is of great significance for the treatment of liver injury thereof. Glycyrrhizin (GL) is a promising inhibitor of the high-mobility group box-1 gene (HMGB1) which is expressed much higher in an inflammatory injury. However, it is not clear whether GL improves ALI via the inhibition of HMGB1. The present study is to probe the function and mechanism of glycyrrhizin on acute liver injury.
MATERIALS AND METHODS: The expression of HMGB1 and inflammation in liver macrophages were analyzed. Lipopolysaccharide (LPS) was used in stimulating the macrophages to activate inflammatory response and recombined human HMGB1 was used to resist the function of GL to explore whether GL acted via the target of HMGB1. Then, LPS injection was utilized to induce ALI in mice, and then we evaluated GL treatment in ALI model.
RESULTS: The results showed that the expressions of HMGB1 and inflammatory factors were markedly increased in LPS-activated liver macrophages. GL inhibited the progress of macrophages inflammation by restraining HMGB1, and the administration of GL could reverse the effects of LPS-induced ALI in mice. Moreover, PI3K/mTOR pathway was significantly suppressed by GL application.
CONCLUSIONS: These results suggest that GL prevents inflammation in liver macrophages via inhibition of HMGB1. GL restrains inflammation and cell apoptosis by inhibiting HMGB1 via PI3K/mTOR signaling pathway in ALI. GL may become a novel drug for the therapy of ALI in the future.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32633407     DOI: 10.26355/eurrev_202006_21706

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Silencing lncRNA TUG1 Alleviates LPS-Induced Mouse Hepatocyte Inflammation by Targeting miR-140/TNF.

Authors:  Qing-Min Liu; Li-Li Liu; Xi-Dong Li; Ping Tian; Hao Xu; Zeng-Lian Li; Li-Kun Wang
Journal:  Front Cell Dev Biol       Date:  2021-02-11

2.  Co-treatment with disulfiram and glycyrrhizic acid suppresses the inflammatory response of chondrocytes.

Authors:  Chao Li; Li Li; Tian Lan
Journal:  J Orthop Surg Res       Date:  2021-02-12       Impact factor: 2.359

Review 3.  High Mobility Group Box 1: Biological Functions and Relevance in Oxidative Stress Related Chronic Diseases.

Authors:  Simona Taverna; Alessandro Tonacci; Maria Ferraro; Giuseppe Cammarata; Giuseppina Cuttitta; Salvatore Bucchieri; Elisabetta Pace; Sebastiano Gangemi
Journal:  Cells       Date:  2022-03-01       Impact factor: 6.600

Review 4.  Research progress on extraction technology and biomedical function of natural sugar substitutes.

Authors:  Pengyu Lei; Haojie Chen; Jiahui Ma; Yimen Fang; Linkai Qu; Qinsi Yang; Bo Peng; Xingxing Zhang; Libo Jin; Da Sun
Journal:  Front Nutr       Date:  2022-08-03

Review 5.  Protective role of ethyl pyruvate in spinal cord injury by inhibiting the high mobility group box-1/toll-like receptor4/nuclear factor-kappa B signaling pathway.

Authors:  Ruihua Fan; Lvxia Wang; Benson O A Botchway; Yong Zhang; Xuehong Liu
Journal:  Front Mol Neurosci       Date:  2022-09-16       Impact factor: 6.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.